Genetic Technologies Ltd (ASX: GTG) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Genetic Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.97 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 96.57 million
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -31.85%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Genetic Technologies Ltd (ASX: GTG)
    Latest News

    a woman
    ⏸️ Investing

    Market wipeout: Stocks crushed in $24 billion rush for the exits

    S&P/ASX 200 sinks 1.3%, but these stocks fared much worse

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    S&P/ASX 200 closes flat, but these four skyrocketed

    Read more »

    a woman
    ⏸️ Investing

    Genetic Technologies Limited soars 30%: Here's why

    Highly speculative Genetic Technologies Limited (ASX:GTG) could be one to watch

    Read more »

    GTG ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Genetic Technologies Ltd

    Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

    GTG Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.09 $0.00 0.00% 31,318 $0.09 $0.09 $0.09
    20 Jun 2024 $0.09 $0.00 0.00% 19,990 $0.09 $0.09 $0.09
    19 Jun 2024 $0.09 $0.00 0.00% 460,347 $0.09 $0.10 $0.09
    18 Jun 2024 $0.10 $0.00 0.00% 465,050 $0.10 $0.10 $0.09
    17 Jun 2024 $0.10 $0.00 0.00% 13,204 $0.10 $0.10 $0.10
    14 Jun 2024 $0.09 $0.00 0.00% 131,248 $0.10 $0.11 $0.09
    13 Jun 2024 $0.09 $0.00 0.00% 49,562 $0.09 $0.10 $0.09
    12 Jun 2024 $0.09 $-0.01 -10.31% 156,908 $0.09 $0.10 $0.09
    11 Jun 2024 $0.10 $0.00 0.00% 52,443 $0.10 $0.10 $0.09
    07 Jun 2024 $0.10 $0.00 0.00% 52,755 $0.09 $0.10 $0.09
    06 Jun 2024 $0.09 $-0.03 -24.00% 953,287 $0.10 $0.10 $0.09
    05 Jun 2024 $0.13 $0.03 30.00% 265,212 $0.10 $0.13 $0.10
    04 Jun 2024 $0.10 $0.00 0.00% 20,210 $0.10 $0.11 $0.10
    03 Jun 2024 $0.11 $0.00 0.00% 7,216 $0.10 $0.11 $0.10
    31 May 2024 $0.10 $0.00 0.00% 213,369 $0.11 $0.11 $0.10
    30 May 2024 $0.10 $-0.02 -16.67% 555,969 $0.11 $0.11 $0.10
    29 May 2024 $0.12 $0.01 9.09% 341,059 $0.13 $0.14 $0.12
    27 May 2024 $0.11 $0.00 0.00% 34,067 $0.12 $0.12 $0.11

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Mar 2024 Peter Rubinstein Buy 617,209 $80,315
    On-market trade. average price
    21 Dec 2023 Nicholas (Nick) Burrows Expiry 5,000,000 $750,000
    As advised by the company. Expired
    21 Dec 2023 Lindsay Wakefield Expiry 5,000,000 $750,000
    As advised by the company. Expired
    21 Dec 2023 Jerzy (George) Muchnicki Expiry 57,500,000 $8,625,000
    As advised by the company. Expired, As per announcement on 27-12-2023
    21 Dec 2023 Peter Rubinstein Expiry 57,500,000 $8,625,000
    As advised by the company. Expired

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Lindsay Peter Wakefield Non-Executive Director Sep 2014
    Dr Wakefield started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a range of industrial products. In 1993, he left medicine to become the full time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling. Dr Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years
    Dr Jerzy (George) Muchnicki Executive Director Jan 2018
    Dr Muchnicki acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr. Simon Morriss to the role. For the past 14 years, he has been involved in commercialization and funding R&D in the biotechnology sector from gene silencing to regenerative medicine. Dr Muchnicki brings with him commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.
    Mr Peter Irwin Rubinstein Non-Executive ChairmanNon-Executive Director Jan 2018
    Mr Rubinstein has over 20 years' experience in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a national firm prior to moving in-house at Montech, the commercial arm of Monash University. Mr. Rubinstein has had exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy.
    Ms Kathryn Andrews Chief Financial OfficerCompany Secretary Mar 2024
    -
    Mr Simon Morriss Chief Executive Officer Feb 2021
    -
    Carl Stubbings Chief Commercial Officer
    -
    Simon Morriss Chief Executive Officer
    -
    Simon Morriss Chief Executive Officer
    -
    Kevin Camilleri Chief Executive Officer of EasyDNA
    -
    Kathryn Andrews Chief Financial OfficerCompany Secretary
    -
    Richard Allman Scientific Advisor former Chief Scientific Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 8,119,123,510 70.35%
    Mr Warwick Wright 217,500,000 1.88%
    Mjgd Nominees Pty Ltd 200,849,309 1.74%
    Doma 193 Pty Ltd <Doma 193 A/C> 144,551,379 1.25%
    Rip Opportunities Pty Ltd <Pir Super Fund A/C> 124,999,999 1.08%
    Irwin Biotech Nominees Pty Ltd <Bioa A/C> 75,849,310 0.66%
    Ap 300 Pty Ltd <Ap Invest A/C> 48,040,000 0.42%
    Monument Hill Pty Ltd 42,000,001 0.36%
    Miss Susan Spiteri 40,142,778 0.35%
    Mrs Helen Kamer & Mr Benjamin Kamer <Kamer Super Fund A/C> 40,000,000 0.35%
    Mr Lei Da Tao 38,000,000 0.33%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 35,043,531 0.30%
    Aquasafe Investments Pty Ltd <White Superfund A/C> 30,608,028 0.27%
    Whalecorp Pty Ltd <Whalecorp Pty Ltd S/F A/C> 30,000,000 0.26%
    Miss Beverley Susan Mccain 28,000,000 0.24%
    Mr John Christopolous <Chrisand Family A/C> 27,000,000 0.23%
    Mr Bill Gianoulas 25,000,000 0.22%
    Mr Michael Battley 24,221,459 0.21%
    Citicorp Nominees Pty Limited 23,257,576 0.20%
    Mr Can Odabas 23,000,000 0.20%

    Profile

    since

    Note